Real world adjuvant endocrine treatment in premenopausal breast cancer patients compared with the proposed algorithm using the Regan Composite Risk Score.

Dr. Vangoitsenhoven from KU Leuven evaluated how the adjuvant endocrine therapy policy at their hospital evolved over time. In a retrospective cohort study in premenopausal breast cancer patients, the adjuvant endocrine treatment policy suggested by the tumour board was compared with the proposed therapy guided by the Regan Composite Risk Score during 2 time periods (before and after the publication of the TEXT and SOFT trials).

The Regan Composite Risk Score (RCRS) is a web-based prognostic and predictive calculator to guide the use of adjuvant exemestane plus ovarian function suppression (AI + OFS) versus tamoxifen plus ovarian function suppression (TAM + OFS) or tamoxifen alone (TAM) for premenopausal women with hormone receptor-positive HER2-negative early breast cancer (HR+/HER2- EBC).